BEACOPP方案治疗霍奇金淋巴瘤安全性与有效性分析

Efficacy and safety analysis of BEACOPP regimen in the treatment of patients with Hodgkin's Lymphoma

目的探讨BEACOPP方案(博来霉素+依托泊苷+多柔比星+环磷酰胺+长春新碱+甲基苄肼+泼尼松)治疗霍奇金淋巴瘤(hodgkin’s lymphoma,HL)的临床应用价值。方法前瞻性纳入2005-01-01-2009-06-01宜昌市葛洲坝中心医院接受治疗的HL患者80例,采用随机数字表法分为对照组和实验组,每组各40例。对照组采用ABVD方案(多柔比星+博来霉素+长春新碱+达卡巴嗪)治疗;实验组采用BEACOPP方案治疗。观察和比较两组患者的治疗有效率(完全缓解率+部分缓解率)、药物毒副作用和3年生存率。结果实验组患者治疗有效率为95.00%(38/40),高于对照组的85.00%(34/40),差异无统计学意义,χ2=2.222,P=0.126。实验组不良反应发生率为75.00%(30/40),相比对照组的85.00%(34/40)差异无统计学意义,χ2=1.250,P=0.264。实验组患者3年生存率为92.50%(37/40),显著高于对照组的75.00%(30/40),差异有统计学意义,χ2=4.398,P=0.036。结论在进展期HL的治疗上,BEACOPP方案在近期治疗有效率、药物不良反应率与ABVD方案差异无统计学意义,其远期生存率显著高于ABVD方案。

OBJECTIVE This prospective study aimed to investigate the clinical value about BEACOPP regimen （bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, prednisone） in the treatment of patients with Hodgkin＇s lymphoma. METHODS The 80 cases of patients admitted to hospital from 2005-01-01 to 2009-06-01 were randomly divided into two groups, control group （n=40） and treatment group （n：40）. The control group was giv- en ABVD regimen（adriamycin, bleomycin, vincristine, dacarbazine）, the treatment group was given BEACOPP regimen. The short-term efficacy, the survival rates, and the adverse reactions in 2 groups were observed and compared. RESULTS The short-term efficacy in the treatment group（95.00%） was similar with the control group （85.00%, P〉0.05） ; the incidence of side effects in the treatment group（75.00%） were similar with the control group （85.00%, P〉0.05） ; the 3-year overall survival rate in the treatment group（92.50%） was significantly higher than the control group （75.00%, P〈0.05）. CONCLUSIONS The clinical application of BEACOPP regimen in the treatment of Hodgkin＇s lymphoma is safe and reliable,and the long-term efficacy of BEACOPP regimen is better than that of ABVD regimen.